[Enoximone].
Enoximone is a new cardiotonic agent, active by both intravenous and oral routes of administration. Its pharmacological effects are due to the inhibition of the type IV phosphodiesterase: positive inotropism, vasodilatation and positive chronotropic action. The efficacy of enoximone in improving cardiovascular function in patients with congestive heart failure has been documented in many studies, but not in studies having mortality as the main end-point. In conclusion, enoximone cannot be safely proposed yet for the chronic treatment of congestive heart failure in association with classic management, until convincing evidence of its long-term benefit/risk profile will be given.
Ventura
G
G
D000284:Administration, Oral; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy; D004311:Double-Blind Method; D017335:Enoximone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007275:Injections, Intravenous; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone
Enoximone.